INTRODUCTION {#s1}
============

Menopause is characterized by a decrease in estrogen, which triggers the uncomfortable symptoms of hot flushes, night sweats, sleep disturbances, and vaginal dryness. Among these menopausal symptoms, hot flushes are reported by many women to be the most bothersome^[@R1]^. The symptoms of menopause as a result of decreasing estrogen levels can significantly affect quality of life^[@R2]^. While hormone replacement therapy (HRT) effectively reduces vasomotor symptoms associated with the decrease of estrogen levels during menopause, results of the Women\'s Health Initiative (WHI) trial indicated that the benefits of HRT did not outweigh the risks^[@R3]^, as estrogen alone would increase risks of stroke and venous thromboembolism (VTE), and together with progestin could incur additional risks of causing breast cancer and heart attack. As a result, the role of HRT has been limited to treat postmenopausal symptoms at minimal dose and duration, and more efficacious and better tolerated alternatives to decrease menopausal symptoms are still being sought^[@R4]--[@R6]^.

Phytoestrogens are plant compounds with estrogen-like properties^[@R7]^. The two major classes of phytoestrogens are isoflavones and lignans; soybeans are rich in isoflavones, and lignans are found in flaxseed, whole grains, legumes, fruits, and vegetables^[@R8]^. The chemical structures of isoflavones and lignans are similar to that of estradiol, and these compounds appear to exert an estrogenic or antiestrogenic effect depending on the circulating estrogen level (i.e. they exert an antiestrogenic effect when the circulating estrogen level is high, but when the estrogen level is low, their effect becomes more estrogenic)^[@R7]^. There is much interest in the use of phytoestrogens to treat menopausal symptoms, in part because vasomotor symptoms are much less frequently experienced by Asian women than by women in America or Europe^[@R9]^, and because the Asian diet being rich in phytoestrogens may be a contributing factor^[@R10]^. Though there has been a large amount of research devoted to determine whether phytoestrogens are well tolerated and effective for the treatment of menopausal symptoms, study results have been inconclusive and no consensus on their utility has been reached^[@R7],[@R11],[@R12]^. Conflicting data may be due to multiple factors including variations in studies\' inclusion criteria, types and dosages of consumed phytoestrogens, the lack of appropriate study controls, control for the consumption of phytoestrogens from other sources, and differences in the outcome measures used^[@R7],[@R11],[@R12]^. There is also a need for more well-funded studies on potential long-term adverse effects of phytoestrogens such as heart diseases, breast cancer, VTE and stroke.

The purpose of this study was to perform a meta-analysis of high-quality, randomized, controlled trials (RCTs), to evaluate the effectiveness and short-term side-effects of phytoestrogens in alleviating menopausal symptoms and improving quality of life.

METHODS {#s2}
=======

Literature search strategy {#s3}
--------------------------

Medline, Cochrane, EMBASE and Google Scholar databases were searched until September 30, 2013 using combinations of the following key words: vasomotor symptoms, menopausal symptoms, phytoestrogens, isoflavones, coumestrol, soy, red clover. Reference lists of relevant studies were hand-searched.

Inclusion criteria for this meta-analysis were (1) RCT, (2) subjects were perimenopausal or postmenopausal women experiencing menopausal symptoms, (3) the intervention was a phytoestrogen (e.g. isoflavone, genistein, soy extract), and (4) the intervention was in oral form. Studies were excluded from the analysis if (1) there was no placebo control group, (2) there was only an active control group (e.g. hormone replacement therapy), and (3) numerical outcome data were not provided.

Study selection, data extraction and quality assessment {#s4}
-------------------------------------------------------

Studies were identified via the search strategy by two independent reviewers. When there was uncertainty regarding eligibility, a third reviewer would be consulted. The following information/data were extracted from studies that met the inclusion criteria: the name of the first author, year of publication, study design, participants\' age and gender, diagnosis, number of participants in each treatment group, treatment, length of follow-up, function and quality-of-life outcomes, and side-effects. The Delphi list was used to assess the quality of the included studies^[@R13]^.

Outcome measures {#s5}
----------------

Outcome measures included changes in Kupperman index (KI)^[@R14]^, changes in daily hot flush frequency, and the likelihood of side-effects. Briefly, the Kupperman index covers 11 menopausal symptoms including hot flushes (vasomotor), paresthesia, insomnia, nervousness, melancholia, vertigo, weakness, arthralgia or myalgia, headache, palpitations, and formication. Each symptom is rated on a scale from 0 to 3 for having no, slight, moderate or severe complaints, respectively, with the highest possible total score being 51.

Statistical analysis {#s6}
--------------------

The mean differences between treatment groups in changes in KI and daily hot flush frequency were calculated to evaluate the efficacy of phytoestrogens, and the odds ratios (ORs) of side-effects occurring were calculated to evaluate the safety of phytoestrogens. A χ^2^-based test of homogeneity was performed using Cochran\'s *Q* statistic and *I*^2^. The percentage of the total variability in effect estimates among trials that are due to heterogeneity rather than chance is expressed by *I*^2^. Random-effects models of analysis were used if heterogeneity was detected (*Q* statistic with *p* \< 0.1 or *I*^2^ \> 50%). The pooled estimates of mean differences in KI change, mean differences in change of daily hot flush frequency, and the pooled estimates of ORs of side-effects were calculated. Sensitivity analysis was performed based on the leave-one-out approach. The one-sided Egger\'s test and Funnel plots were performed to evaluate publication bias. The homogeneity test, pooled estimates, and sensitivity analysis were performed by using Comprehensive Meta-Analysis, version 2.0 (Biostat, Englewood, NJ, USA). A value of *p* \< 0.05 indicates statistical significance.

RESULTS {#s7}
=======

Literature search and study characteristics {#s8}
-------------------------------------------

A flow diagram of study selection is shown in [Figure 1](#F1){ref-type="fig"}. A total of 543 potentially relevant articles were initially identified and screened, and 488 of them were subsequently excluded. Of the 55 full-text articles reviewed, 40 were excluded and ultimately 15 studies^[@R11],[@R15]--[@R28]^ were included in the meta-analysis.

![Flow diagram of study selection](dcli18_260_f1){#F1}

The characteristics and outcomes of the 15 studies are summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

General characteristics of the 15 studies included in the meta-analysis. Age is presented as mean (standard deviation)

  *1st author, year of publication*   *Number of women*   *Inclusion criteria*                                                             *Intervention (compound, daily dose)*                           *Intervention period* (months)   *Age* (years)   
  ----------------------------------- ------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------- -------------------------------- --------------- --------------
  Aso, 2012^[@R15]^                   160                 Postmenopausal                                                                   S-(−) equol, 5 mg                                               3                                53.9 (3.4)      53.2 (3.6)
  Atkinson, 2004^[@R16]^              205                 Wolfe P2 or DY mammographic breast patterns                                      Isoflavones                                                     12                               55.2 (4.9)      55.1 (4.7)
  Cancellieri, 2007^[@R17]^           142                 Postmenopausal                                                                   Isoflavones, 72 mg                                              6                                54.4 (4.2)      54.1 (5.2)
  Del Giorno, 2010^[@R18]^            120                 Postmenopausal                                                                   Trifolium, 40 mg                                                12                               55.14 (4.97)    55.78 (4.93)
  Ferrari, 2009^[@R19]^               180                 Minimum of five moderate-to-severe hot flushes in last 7 days at baseline        Isoflavones, 80 mg                                              3                                54.9 (4.6)      53.2 (4.3)
  Han, 2002^[@R20]^                   80                  Menopause of at least 12 months                                                  Isoflavones, 100 mg                                             4                                49 (1.3)        48 (1.1)
  Lewis, 2006^[@R11]^                 99                  Natural menopause with last menses 1--8 years before recruitment                 Isoflavones, 42 mg                                              4                                52.9 (3.6)      53.3 (3.1)
  Nahas, 2007^[@R21]^                 80                  Postmenopausal                                                                   Isoflavones, 100 mg                                             10                               56.2 (7.7)      55.1 (6.0)
  Penotti, 2003^[@R22]^               62                  Postmenopausal                                                                   Isoflavones, 36 mg                                              6                                52.5 (2.3)      52.5 (2.5)
  Petri Nahas, 2004^[@R23]^           50                  Menopausal                                                                       Isoflavones, 60 mg                                              6                                52.9 (5.11)     53.7 (5.45)
  Riesco, 2011^[@R24]^                56                  Postmenopausal                                                                   Isoflavones, 25 mg                                              6                                58.3 (5.84)     60.1 (3.67)
  Sammartino, 2006^[@R25]^            80                  Postmenopausal                                                                   Isoflavones 60 mg; lignans 100 mg                               3                                50.6 (1.75)     50.9 (1.85)
  Tice, 2003^[@R26]^                  252                 Menopausal; 45--60 years of age; experiencing at least 35 hot flushes per week   Isoflavones, 82 mg (Promensil); Isoflavones, 57 mg (Rimostil)   3                                52.3 (3.4)      52.3 (2.9)
  Van de Weijer, 2002^[@R27]^         30                  Postmenopausal                                                                   Isoflavones, 82 mg                                              3                                52.5 (5.2)      54.2 (7.4)
  Van Patten, 2002^[@R28]^            157                 Postmenopausal with breast cancer                                                Isoflavones, 90 mg                                              3                                54.9 (6.5)      55.5 (6.3)

###### 

Summary of Kupperman index and hot flush frequency reported in the studies included in the meta-analysis. Data are given as mean (standard deviation), except for side-effects which are reported as a number

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          *Number of women*   *Baseline KI*   *KI after intervention*                     *Baseline hot flush frequency (/day)*     *Hot flush frequency after intervention (/day)*   *Side-effect number*                                                                                                                            
  ----------------------- ------------------- --------------- ------------------------------------------- ----------------------------------------- ------------------------------------------------- ---------------------------------------- ------------- ------------- ---------------------------------- ---------------------------------- ---- ----
  Aso^[@R15]^             60                  66                                                                                                                                                                                               2.9 (2.1)     3.2 (2.4)     1.9 (NA)\                          1.3 (NA)\                               
                                                                                                                                                                                                                                                                           change from baseline: −1.0 (2.0)   change from baseline: −1.9 (1.8)        

  Atkinson^[@R16]^        103                 102                                                                                                                                                                                              2.5 (3.0)     2.1 (2.7)     1.5 (2.0)\                         1.2 (2.3)\                              
                                                                                                                                                                                                                                                                           change from baseline: −1.0 (1.8)   change from baseline: −0.8 (2.1)        

  Cancellieri^[@R17]^     65                  60              19.6 (8.5)                                  20.8 (9.1)                                12.2 (7.2)                                        9.6 (5.7)                                                                                                                                       

  Del Giorno^[@R18]^      50                  50              25.12 (9.02)                                25.34 (10.17)                             12.01 (9.01)                                      11.12 (8.68)                                                                                                                                    

  Ferrari^[@R19]^         94                  82              23.5 (7.1)                                  23.4 (8.3)                                16.1 (7.6)                                        17.5 (10.0)                              7.5 (2.8)     8.0 (3.3)     5.3 (3.8)                          4.7 (4.2)                          8    6

  Han^[@R20]^             40                  40              40.3 (7.6)                                  44.6 (6.3)                                41.6 (7.0)                                        24.9 (10.8)                                                                                                                                     

  Lewis^[@R11]^           33                  33                                                                                                                                                                                               4.72 (3.04)   4.08 (2.38)   3.79 (3.00)                        3.37 (2.55)                             

  Nahas^[@R21]^           38                  38                                                                                                                                                                                               10.1 (4.9)    9.6 (3.9)     5.9 (4.3)                          3.1 (2.3)                          4    7

  Penotti^[@R22]^         34                  28                                                                                                                                                                                               8.6 (2.9)     9.9 (4.5)     4.0 (3.9)                          4.6 (3.8)                               

  Petri Nahas^[@R23]^     25                  26              20.05 (6.14)                                21.10 (6.11)                              13.5 (5.0)                                        12 (6.0)                                 6.4 (2.4)     7 (1.8)       5.2 (2.8)                          3.0 (2.1)                          2    7

  Riesco^[@R24]^          21                  19              17.0 (9.35)                                 13.3 (9.9)                                15.7 (9.0)                                        12.3 (9.56)                                                                                                                                     

  Sammartino^[@R25]^      36                  39              31 (2.5)[∗](#T2-FN1){ref-type="table-fn"}   31 (3)[∗](#T2-FN1){ref-type="table-fn"}   26 (1.5)[∗](#T2-FN1){ref-type="table-fn"}         8 (1)[∗](#T2-FN1){ref-type="table-fn"}                                                                                                          

  Tice^[@R26]^            85                  167                                                                                                                                                                                              7.8 (2.35)    8.3 (3.83)    5.0 (3.76)                         5.25 (4.17)                        33   59

  van de Weijer^[@R27]^   14                  16                                                                                                                                                                                               5.75 (5)      5.43 (2.6)    6.04 (5.5)                         3.35 (3)                                

  Van Patten^[@R28]^      64                  59                                                                                                                                                                                               7.4 (6.4)     7.1 (4.3)     4.9 (3.9)                          5.3 (4.1)                          14   28
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

KI, Kupperman index; Phyto, phytoestrogen; NA, not available

^∗^, Mean and standard deviation were estimated from median and range^[@R29]^

The mean age of the subjects ranged from 49 to 58.3 and 48 to 60.1 years, in the placebo and phytoestrogen groups, respectively. The number of participants in the studies ranged from 30 to 252, and the intervention periods ranged from 3 to 12 months. Seven studies reported the KI at baseline and after intervention^[@R17]--[@R20],[@R23]--[@R25]^, while ten studies reported hot flush frequency at baseline and after intervention, or change from baseline^[@R11],[@R15],[@R16],[@R19],[@R21]--[@R23],[@R26]--[@R28]^. As expected, there was no significant difference in baseline KI and hot flush frequency between treatment and placebo groups, since the participants were randomly allocated. Only five studies reported the number of side-effects^[@R19],[@R21],[@R23],[@R26],[@R28]^.

Change in Kupperman index {#s9}
-------------------------

Of the seven studies that reported KI data^[@R17]--[@R20],[@R23]--[@R25]^, three reported a significant reduction of KI in the phytoestrogen group when compared with the placebo group^[@R17],[@R20],[@R25]^, while the other four^[@R18],[@R19],[@R23],[@R24]^ reported no difference between the groups. Meta-analysis of the seven studies indicated no significant treatment effect of phytoestrogen when compared to placebo (pooled mean difference = 6.4, *p* = 0.110, [Figure 2a](#F2){ref-type="fig"}). The pooled estimate remained positive and non-significant after sensitivity analysis based on the leave-one-out approach was made, indicating there was no influence of individual studies on the pooled estimate ([Figure 2b](#F2){ref-type="fig"}).

![Meta-analysis (a) with sensitivity evaluation (b) for change in Kupperman index between placebo and phytoestrogen groups (seven studies included). The random-effects approach was used due to significant heterogeneity (*Q* = 370.03, *I*^2^ = 98.38, *p* \< 0.001). CI, confidence interval](dcli18_260_f2){#F2}

Daily hot flush frequency {#s10}
-------------------------

Of the ten studies that reported hot flush frequency data^[@R11],[@R15],[@R16],[@R19],[@R21]--[@R23],[@R26]--[@R28]^, four reported a significant reduction of hot flush frequency in the phytoestrogen group when compared to the placebo group^[@R15],[@R19],[@R21],[@R23]^, while the other six^[@R11],[@R16],[@R22],[@R26]--[@R28]^ reported no significant difference between the groups. Meta-analysis of the ten studies indicated that the phytoestrogen group had a significant reduction in hot flush frequency when compared with the placebo (pooled mean difference = 0.89, *p* \< 0.005, [Figure 3a](#F3){ref-type="fig"}). The pooled estimate remained positive and significant after sensitivity analysis based on the leave-one-out approach was made, indicating there was no influence of individual studies on the pooled estimate ([Figure 3b](#F3){ref-type="fig"}).

![Meta-analysis (a) with sensitivity evaluation (b) for change of hot flush frequency between placebo and phytoestrogen groups (10 studies included). The random-effects approach was used due to significant heterogeneity (*Q* = 22.75, *I*^2^ = 60.43, *p* = 0.007). CI, confidence interval](dcli18_260_f3){#F3}

Likelihood of side-effects {#s11}
--------------------------

Four^[@R19],[@R21],[@R23],[@R26]^ of the five studies that reported the number of side-effects showed no significant difference in the numbers of side-effects between groups. The study by Van Patten and colleagues^[@R28]^ reported that the subjects in phytoestrogen group were less likely to experience side-effects than those in the placebo group (OR = 0.31, *p* = 0.003). Meta-analysis of the five studies showed no significant difference in side-effects between the two groups (*p* = 0.175, [Figure 4a](#F4){ref-type="fig"}). With the exception of the study by Tice and colleagues^[@R26]^, when each of the other studies was removed in turn, the pooled ORs remained \< 1 and non-significant. When the study by Tice and colleagues^[@R26]^ was removed, the pooled OR reached statistical significance (*p* = 0.034) ([Figure 4b](#F4){ref-type="fig"}).

![Meta-analysis (a) with sensitivity evaluation (b) for the likelihood of side-effects between the placebo and phytoestrogen groups (five studies included). The random-effects approach was used due to significant heterogeneity (*Q* = 10.15, *I*^2^ = 60.60, *p* = 0.038). OR, odds ratio; CI, confidence interval](dcli18_260_f4){#F4}

Evaluation of publication bias {#s12}
------------------------------

Egger\'s test for KI (seven studies)^[@R17]--[@R20],[@R23]--[@R25]^ showed the estimated intercept to be −10.01, with a one-tailed *p* value = 0.043, which indicated a significant asymmetry in the funnel plot ([Figure 5a](#F5){ref-type="fig"}). Egger\'s test for hot flush frequency (ten studies)^[@R11],[@R15],[@R16],[@R19],[@R21]--[@R23],[@R26]--[@R28]^ showed the estimated intercept to be 2.99, with a one-tailed *p* value = 0.036, which indicated a significant asymmetry in the funnel plot ([Figure 5b](#F5){ref-type="fig"}). Egger\'s test for side-effects (five studies)^[@R19],[@R21],[@R23],[@R26],[@R28]^ showed the estimated intercept to be −1.92 with one-tailed *p* value of 0.185 (non-significant) which indicated no significant asymmetry in the funnel plot ([Figure 5c](#F5){ref-type="fig"}).

![Evaluation of publication bias for (a) Kupperman index, (b) hot flush frequency, and (c) side-effects](dcli18_260_f5){#F5}

Quality assessment {#s13}
------------------

Results of the analysis of quality assessment are shown in [Figure 6](#F6){ref-type="fig"}.

![Quality assessment](dcli18_260_f6){#F6}

DISCUSSION {#s14}
==========

Phytoestrogens are commonly used for the relief of menopausal symptoms, but studies have provided conflicting results of their efficacy. The results of this meta-analysis including 15 high-quality RCTs showed that, although the use of phytoestrogens did not result in a change of KI when compared to the use of placebo, they did significantly reduce the frequency of hot flushes as compared with the placebo. In addition, there was no difference in the occurrence of side-effects between patients who received phytoestrogens and those who received placebo.

There is a large body of research devoted to determine the efficacy of phytoestrogens in treating menopausal symptoms, and a search of PubMed using the terms "phytoestrogen, menopause" produces well over 800 results. However, results of many studies are conflicting and there is still a lack of consensus on their efficacy^[@R7],[@R12],[@R30]^. Some of the reasons for these conflicting data include variations in the study design, variable types and dosage of consumed phytoestrogen, lack of appropriate study controls, a lack of controls for the consumption of phytoestrogens from other sources, and differences in the outcome measures used^[@R7],[@R11],[@R12]^. Although many studies have shown phytoestrogens can reduce the vasomotor symptoms of menopause^[@R15],[@R17],[@R19]--[@R23],[@R25],[@R27]^, many others have not^[@R11],[@R16],[@R18],[@R22],[@R24],[@R26],[@R28]^. Two recent reviews and meta-analyses have found little conclusive evidence on the effectiveness of phytoestrogens for treating vasomotor symptoms associated with menopause^[@R12],[@R30]^. In 2009, Jacobs and colleagues^[@R30]^ performed a systematic review of the literature including 17 randomized and placebo-controlled trials that investigated soy isoflavones and reported that the interventions and outcome measures in those studies were so highly heterogeneous that a meta-analysis could not be made. Their systematic review decided that there were qualitative deficiencies in the studies and a consistent reduction in hot flushes was not present. A more recent (2013) Cochrane review of the literature of phytoestrogens for menopausal vasomotor symptoms had included 43 RCTs with a total of 4364 participants, but found that very few studies actually provided data suitable for meta-analysis, so they too were unable to reach a conclusion on the efficacy of phytoestrogens^[@R12]^.

A recent review of five meta-analyses and one review investigating the impact of phytoestrogens on menopausal symptoms concluded that isoflavones did not relieve menopausal vasomotor symptoms^[@R31]^. Our meta-analysis indicated that phytoestrogens did not result in a significant decrease of the KI, but did reduce the frequency of hot flushes compared with placebo. Hot flushes occur in up to 74% of postmenopausal women and can have a negative impact on quality of life; they can still be experienced by some women in their seventies^[@R32]^. The Kupperman index represents more comprehensive grouping of 11 menopausal symptoms which include not only hot flushes (vasomotor), but also paresthesia, insomnia, nervousness, melancholia, vertigo, weakness, arthralgia/myalgia, headache, palpitations, and formication. The lack of significant reduction in KI found in our analysis does cast doubt on the utility of phytoestrogens in alleviating menopausal symptoms other than hot flushes. It is also important to note the high heterogeneity among the included studies in this meta-analysis. There were differences in participant numbers, ages, doses used and outcomes which were recorded. Only seven studies reported KI data, while five studies recorded side-effects and ten studies reported frequency of hot flushes. This wide heterogeneity makes interpretation of data challenging.

A review by Bolanos and colleagues^[@R33]^ in 2010 specifically examined soy isoflavones versus placebo in the treatment of menopausal vasomotor symptoms and found that, although there was a tendency to favor the effectiveness of soy isoflavones, the heterogeneity of studies was high. In the aforementioned Cochrane review^[@R12]^, three placebo-controlled studies reported a significant reduction in the frequency of hot flushes from the use of soy extracts as compared with placebo (21%, 43% and 38% reduction, respectively). Few studies have compared the effect of phytoestrogens or soy products with HRT. In a double-blind, RCT of low-dose hormone therapy, Carmignani and colleagues^[@R34]^ treated symptomatic postmenopausal women with either a regimen of 1 mg estradiol and 0.5 mg norethisterone acetate, daily dietary soy supplementation containing 90 mg of isoflavone, or placebo for 16 weeks and reported that patients who received soy supplementation and hormone therapy had a 49.8% and 45.6% reduction in hot flushes, respectively. Similarly, Crisafulli and colleagues^[@R35]^ evaluated the effects of the phytoestrogen genistein (an isoflavone), estrogen--progesterone HRT, and placebo on hot flushes in postmenopausal women and reported a 22% daily reduction in hot flushes in the genistein group after 12 weeks of treatment when compared with placebo, and a 53% reduction after 12 weeks when compared with placebo in the HRT group. Interestingly, decreased estrogen levels at menopause were accompanied by a significant decrease in BRCA1 and BRCA2 mRNA levels in placebo-treated women, but this was reversed in genistein-treated women^[@R36]^. Bone mineral density for femoral neck and lumbar spine was higher in genistein-treated women compared to placebo^[@R36]^, and genistein did not significantly increase the risk of hypothyroidism compared to placebo^[@R37]^. Furthermore, a randomized trial of 224 postmenopausal women showed no significant difference in endometrial thickness or rates of endometrial hyperplasia or cancer in women receiving an isoflavone soy protein supplement compared to placebo-treated women^[@R38]^.

Lignans have not been as extensively studied as isoflavones, but the currently available data suggest that their effectiveness for reducing the vasomotor symptoms of menopause was no better than placebo. A double-blind, placebo-controlled RCT performed in 2010 by Simbalista and colleagues^[@R39]^ studied two groups of postmenopausal women with one group consuming two slices of bread containing 25 g of flaxseed (46 mg lignans) and the other group consuming wheat bran (\< 1 mg lignans; control group) daily for 12 weeks, and reported similar reduction in hot flush frequency and KI in both groups. Likewise, Pruthi and colleagues^[@R40]^ randomized 188 postmenopausal women to consume a flaxseed bar (410 mg of lignan) or a placebo bar daily for 6 weeks, and found that in both groups there were approximately one-third of women reported a 50% reduction in hot flushes.

The majority of studies examining the roles of phytoestrogens in alleviating menopausal symptoms do not investigate their potential side-effects; of the 15 RCTs included in this meta-analysis, only five reported side-effect data. However, these studies were consistent with the results of this analysis, because they also found side-effects of phytoestrogen consumption to be no different from that with placebo. Most studies indicate that phytoestrogens are well tolerated without serious side-effects^[@R12],[@R31],[@R41]^. Our side-effect data were consistent with a recent meta-analysis which reviewed 174 RCTs and reported that phytoestrogens had a safe side-effect profile^[@R42]^. The rates of hormonal side-effects such as endometrial hyperplasia, endometrial cancer and breast cancer were no higher among phytoestrogen-treated women than placebo-treated women^[@R42]^. Though data are not conclusive, consumption of isoflavones by menopausal women^[@R7]^ may have a positive impact on vaginal atrophy, sleep disturbances, bone mineral density, and cognition. In addition, phytoestrogens do not seem to result in breast cancer or endometrial hyperplasia^[@R7]^, and may actually exert a positive effect on lipid profile^[@R23]^.

There are limitations of this study that should be considered. As with other similar meta-analyses, this meta-analysis is limited by the heterogeneity of the included studies. There was a lack of standardization in dosage used, and the compliance data were not available. In addition, isoflavones were the phytoestrogens used in the majority of the studies, and few studies with other phytoestrogens were included; outcomes with other phytoestrogens were therefore not examined. Furthermore, publication biases detected in the Egger\'s tests for KI as well as frequency of hot flushes might be due to the small number of studies included in this analysis. Despite these shortcomings, the similarities in inclusion criteria and outcome measures among the included studies aided the comparison and analysis.

In conclusion, results of this meta-analysis indicate that, while phytoestrogens did not bring a decrease in KI compared to placebo, their use was associated with a reduction in the hot flush frequency and their side-effects were no more common than those with placebo. While the available data do not support the recommendation of phytoestrogens for relief of all menopausal symptoms, some patients may benefit from their use in reducing hot flushes as these compounds also seem to be well tolerated. As the current data are inconclusive, further study of phytoestrogens for the relief of menopausal symptoms and their potential long-term adverse effects is warranted.

*Conflict of interest* The authors report no conflict of interest. The authors alone are responsible for the content and writing of this paper.

*Source of funding* Nil.
